VPBT Holdings — ProFund VP Biotechnology
All 151 reported holdings of ProFund VP Biotechnology (VPBT) by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets | Value (USD) |
|---|---|---|
| Agpxx | 3.38% | $1.65M |
| Apogee Therapeutics, Inc. | 1.45% | $706.52K |
| Moderna, Inc. | 1.37% | $670.47K |
| Twist Bioscience Corp. | 1.37% | $668.41K |
| Oruka Therapeutics, Inc. | 1.34% | $654.39K |
| Kymera Therapeutics, Inc. | 1.32% | $645.36K |
| Viking Therapeutics, Inc. | 1.27% | $618.93K |
| Praxis Precision Medicines, Inc. | 1.26% | $612.67K |
| Erasca, Inc. | 1.24% | $603.30K |
| Revolution Medicines, Inc. | 1.17% | $571.95K |
| Rhythm Pharmaceuticals, Inc. | 1.17% | $570.36K |
| Cg Oncology, Inc. | 1.17% | $569.61K |
| Sellas Life Sciences Group, Inc. | 1.16% | $564.76K |
| Vaxcyte, Inc. | 1.15% | $563.51K |
| Dianthus Therapeutics, Inc. | 1.15% | $561.58K |
| Cytokinetics, Inc. | 1.15% | $559.27K |
| Natera, Inc. | 1.13% | $552.13K |
| Scholar Rock Holding Corp. | 1.13% | $549.23K |
| Roivant Sciences Ltd. | 1.12% | $548.47K |
| Mirum Pharmaceuticals, Inc. | 1.12% | $548.36K |
| Cogent Biosciences, Inc. | 1.11% | $543.00K |
| Ultragenyx Pharmaceutical, Inc. | 1.11% | $541.39K |
| Travere Therapeutics, Inc. | 1.10% | $535.15K |
| Alkermes PLC | 1.08% | $526.20K |
| Krystal Biotech, Inc. | 1.07% | $523.68K |
| Celcuity, Inc. | 1.07% | $522.05K |
| Relay Therapeutics, Inc. | 1.07% | $521.62K |
| Spyre Therapeutics, Inc. | 1.07% | $520.61K |
| Tg Therapeutics, Inc. | 1.06% | $519.07K |
| Beam Therapeutics, Inc. | 1.05% | $512.40K |
| Protagonist Therapeutics, Inc. | 1.05% | $510.30K |
| Insmed, Inc. | 1.05% | $510.28K |
| Arrowhead Pharmaceuticals, Inc. | 1.04% | $507.40K |
| Vera Therapeutics, Inc. | 1.03% | $502.82K |
| Vertex Pharmaceuticals, Inc. | 1.03% | $502.19K |
| Madrigal Pharmaceuticals, Inc. | 1.03% | $501.51K |
| Abbvie, Inc. | 1.01% | $492.46K |
| Biogen, Inc. | 1.00% | $489.81K |
| Ptc Therapeutics, Inc. | 1.00% | $489.66K |
| Halozyme Therapeutics, Inc. | 1.00% | $488.80K |
| Uniqure NV | 1.00% | $488.10K |
| Bridgebio Pharma, Inc. | 1.00% | $486.50K |
| Crispr Therapeutics AG | 0.99% | $485.73K |
| Immunitybio, Inc. | 0.99% | $483.75K |
| Summit Therapeutics, Inc. | 0.98% | $480.18K |
| Ionis Pharmaceuticals, Inc. | 0.98% | $476.14K |
| Incyte Corp. | 0.97% | $473.62K |
| Amgen, Inc. | 0.97% | $472.20K |
| Neurocrine Biosciences, Inc. | 0.94% | $461.28K |
| Gilead Sciences, Inc. | 0.94% | $457.86K |
| Regeneron Pharmaceuticals, Inc. | 0.94% | $456.43K |
| Exelixis, Inc. | 0.93% | $455.63K |
| Alnylam Pharmaceuticals, Inc. | 0.93% | $455.16K |
| Biomarin Pharmaceutical, Inc. | 0.92% | $448.55K |
| Acadia Pharmaceuticals, Inc. | 0.91% | $444.93K |
| Nuvalent, Inc. | 0.90% | $440.77K |
| Immunovant, Inc. | 0.90% | $438.97K |
| United Therapeutics Corp. | 0.90% | $438.34K |
| Intellia Therapeutics, Inc. | 0.88% | $430.66K |
| Grail, Inc. | 0.88% | $430.31K |
| Biocryst Pharmaceuticals, Inc. | 0.87% | $423.67K |
| Catalyst Pharmaceuticals, Inc. | 0.85% | $414.88K |
| Dyne Therapeutics, Inc. | 0.84% | $407.75K |
| Tango Therapeutics, Inc. | 0.82% | $399.60K |
| Denali Therapeutics, Inc. | 0.81% | $395.24K |
| Veracyte, Inc. | 0.80% | $388.62K |
| Ideaya Biosciences, Inc. | 0.78% | $381.35K |
| Recursion Pharmaceuticals, Inc. | 0.74% | $359.19K |
| Sarepta Therapeutics, Inc. | 0.73% | $354.42K |
| Arcus Biosciences, Inc. | 0.72% | $352.70K |
| Syndax Pharmaceuticals, Inc. | 0.70% | $340.95K |
| Arcutis Biotherapeutics, Inc. | 0.69% | $337.82K |
| Mineralys Therapeutics, Inc. | 0.69% | $336.47K |
| Celldex Therapeutics, Inc. | 0.68% | $333.29K |
| Agios Pharmaceuticals, Inc. | 0.67% | $328.98K |
| Viridian Therapeutics, Inc. | 0.65% | $318.65K |
| Novavax, Inc. | 0.64% | $313.57K |
| Disc Medicine, Inc. | 0.64% | $309.97K |
| Adma Biologics, Inc. | 0.59% | $288.36K |
| Immunome, Inc. | 0.58% | $281.11K |
| Palvella Therapeutics, Inc. | 0.57% | $276.91K |
| Iovance Biotherapeutics, Inc. | 0.55% | $267.32K |
| Absci Corp. | 0.54% | $265.74K |
| Nurix Therapeutics, Inc. | 0.54% | $264.53K |
| Kodiak Sciences, Inc. | 0.53% | $258.30K |
| Biohaven Ltd. | 0.51% | $250.10K |
| Vericel Corp. | 0.48% | $235.57K |
| Anaptysbio, Inc. | 0.48% | $235.37K |
| Capricor Therapeutics, Inc. | 0.47% | $231.89K |
| Stoke Therapeutics, Inc. | 0.47% | $228.29K |
| Monte Rosa Therapeutics, Inc. | 0.46% | $226.80K |
| Vir Biotechnology, Inc. | 0.46% | $223.44K |
| Hyperliquid Strategies, Inc. | 0.45% | $220.86K |
| Tyra Biosciences, Inc. | 0.40% | $197.17K |
| Corvus Pharmaceuticals, Inc. | 0.40% | $194.19K |
| Cullinan Therapeutics, Inc. | 0.39% | $191.97K |
| Precigen, Inc. | 0.37% | $179.07K |
| Inhibrx Biosciences, Inc. | 0.35% | $168.47K |
| Taysha Gene Therapies, Inc. | 0.34% | $168.04K |
| Ardelyx, Inc. | 0.34% | $167.71K |
| Avalo Therapeutics, Inc. | 0.34% | $166.28K |
| Mannkind Corp. | 0.33% | $160.88K |
| Annexon, Inc. | 0.32% | $157.82K |
| Oric Pharmaceuticals, Inc. | 0.32% | $156.79K |
| Zenas Biopharma, Inc. | 0.31% | $151.85K |
| Jade Biosciences, Inc. | 0.31% | $151.10K |
| Olema Pharmaceuticals, Inc. | 0.31% | $150.70K |
| Kura Oncology, Inc. | 0.31% | $149.58K |
| Caredx, Inc. | 0.30% | $144.47K |
| Bicara Therapeutics, Inc. | 0.30% | $144.35K |
| Vor Biopharma, Inc. | 0.29% | $143.34K |
| Xencor, Inc. | 0.28% | $138.46K |
| Arrivent Biopharma, Inc. | 0.28% | $135.10K |
| Replimune Group, Inc. | 0.28% | $134.81K |
| Cytomx Therapeutics, Inc. | 0.27% | $132.41K |
| Janux Therapeutics, Inc. | 0.27% | $131.33K |
| Sionna Therapeutics, Inc. | 0.26% | $126.34K |
| Geron Corp. | 0.25% | $123.81K |
| Solid Biosciences, Inc. | 0.23% | $114.38K |
| Rigel Pharmaceuticals, Inc. | 0.23% | $112.78K |
| Allogene Therapeutics, Inc. | 0.23% | $111.98K |
| Sana Biotechnology, Inc. | 0.22% | $109.51K |
| Altimmune, Inc. | 0.22% | $109.13K |
| Regenxbio, Inc. | 0.21% | $104.05K |
| Ironwood Pharmaceuticals, Inc. | 0.21% | $102.66K |
| Immix Biopharma, Inc. | 0.20% | $96.18K |
| Ocugen, Inc. | 0.19% | $94.88K |
| 4d Molecular Therapeutics, Inc. | 0.19% | $94.86K |
| Candel Therapeutics, Inc. | 0.19% | $92.42K |
| Savara, Inc. | 0.18% | $87.29K |
| Prime Medicine, Inc. | 0.18% | $85.50K |
| First Tracks Biotherapeutics, Inc. | 0.17% | $83.00K |
| Damora Therapeutics, Inc. | 0.17% | $82.45K |
| Ars Pharmaceuticals, Inc. | 0.17% | $81.22K |
| Maplight Therapeutics, Inc. | 0.16% | $79.21K |
| Arbutus Biopharma Corp. | 0.16% | $78.22K |
| Myriad Genetics, Inc. | 0.16% | $76.34K |
| Cabaletta Bio, Inc. | 0.15% | $72.48K |
| Compass Therapeutics, Inc. | 0.14% | $66.41K |
| Emergent Biosolutions, Inc. | 0.13% | $63.39K |
| Prothena Corp. PLC | 0.13% | $63.08K |
| Vanda Pharmaceuticals, Inc. | 0.13% | $62.19K |
| Perspective Therapeutics, Inc. | 0.12% | $61.02K |
| Ovid Therapeutics, Inc. | 0.12% | $58.69K |
| Verastem, Inc. | 0.12% | $57.40K |
| Mimedx Group, Inc. | 0.10% | $50.47K |
| Lexeo Therapeutics, Inc. | 0.10% | $50.14K |
| Achieve Life Sciences, Inc. | 0.08% | $39.08K |
| Sagimet Biosciences, Inc. | 0.07% | $33.70K |
| Bridgebio Oncology Therapeutics, Inc. | 0.06% | $27.48K |
VPBT overview: performance, fees, allocation and SEC filings